Source: Medicines & Healthcare Products Regulatory Agency (GB) Revision Year: 2019 Publisher: Mylan Products Ltd., Station Close, Potters Bar, Herts, EN6 1TL, United Kingdom
Pharmacotherapeutic group: Pyrimidine analogues
ATC code: L01BC02
Efudix is a topical cytostatic preparation which exerts a beneficial therapeutic effect on neoplastic and pre-neoplastic skin lesions while having less effect on normal cells. The pattern of response follows this sequence: erythema, vesiculation, erosion, ulceration, necrosis and epithelisation.
Fluorouracil is minimally systemically absorbed when applied topically to intact skin. When applied to the skin, the skin’s barrier function is pathologically altered (e.g., as in ulceration), and the absorption rate can increase to 60%. In patients with AK, 2.4-6% of the topical dose was absorbed systemically. Similarly, under occlusion, significantly more fluorouracil is absorbed.
Fluorouracil may be metabolised by catabolic or anabolic routes which are similar to that of endogenous uracil.
There is evidence from animal work that fluorouracil is teratogenic.
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
